Sitravatinib

DB15036InvestigationalSmall molecule

Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).

Formula / weight: C₃₃H₂₉F₂N₅O₄S · 629.68 g/mol (avg)
Code names: MGCD516

Resolves to

Compound

UNIICWG62Q1VTBCAS1123837-84-2ChEMBLCHEMBL3989926

Clinical / RWD

ATCL01EX26

Structure

InChIKeyWLAVZAAODLTUSW-UHFFFAOYSA-NSMILESCOCCNCC1=CC=C(N=C1)C1=CC2=C(S1)C(OC1=C(F)C=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2

Targets

P07949RETP35968KDRP35916FLT4P08581MET

What you can answer from here — as of September 15, 2025

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

33Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 6 drug categories

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sitravatinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account